文献速递胸部肿瘤

NRG1融合驱动肺癌的临床病理特征与治疗反应:eNRGy1全球多中心注册研究

Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
PubMed 文献 · J Clin Oncol · 2021-06-02

eNRGy1全球注册研究纳入110例病理确诊的NRG1融合阳性肺癌患者,发现该群体分子、病理和临床异质性高于既往认知;铂双药、紫杉类、化疗联合免疫及单药免疫疗效均有限,阿法替尼客观缓解率25%。

要点

  • NRG1融合肺癌中不吸烟、黏液腺癌、非转移表型常见,但吸烟史和非黏液/非腺癌组织学亦占一定比例。
  • 铂双药和紫杉类化疗ORR低(13%和14%),中位PFS分别为5.8和4.0个月。
  • 阿法替尼ORR为25%,中位PFS 2.8个月,不依赖融合类型。

核心结论

  • NRG1融合阳性肺癌在分子、病理和临床上比既往认识更具异质性,细胞毒、免疫和靶向治疗活性均不理想。

研究设计与样本

  • 全球多中心注册研究,2018年6月至2020年2月纳入22个中心、9个国家的110例病理确诊NRG1融合阳性肺癌患者,集中分析临床、病理、分子及RECIST v1.1疗效数据。

主要发现

  • 110例患者中,从不吸烟者占57%,黏液腺癌占57%,非转移者占71%,吸烟史者占43%,非黏液腺癌占43%,非腺癌占6%。
  • RNA-based检测发现大多数融合(74%),鉴定出18个5' Partner中6个新型、20个独特包含EGF结构域的嵌合事件及异质性5'/3'断点。
  • 铂双药化疗ORR为13%,中位PFS 5.8个月;铂双药后紫杉类化疗ORR为14%,中位PFS 4.0个月。
  • 化疗联合免疫治疗ORR为0%、中位PFS 3.3个月;单药免疫治疗ORR为20%、中位PFS 3.6个月。
  • 阿法替尼ORR为25%,不依赖融合类型,中位PFS 2.8个月。

关键数值与推荐

  • PD-L1表达率为28%,肿瘤突变负荷中位数为0.9 mutations/megabase。
  • 铂双药化疗ORR 13%、中位PFS 5.8个月;紫杉类化疗ORR 14%、中位PFS 4.0个月。
  • 化疗联合免疫治疗ORR 0%、中位PFS 3.3个月;单药免疫治疗ORR 20%、中位PFS 3.6个月。
  • 阿法替尼ORR 25%、中位PFS 2.8个月。

临床怎么用

  • NRG1融合肺癌应优先采用RNA-based检测以明确融合。
  • 传统化疗、免疫治疗及阿法替尼疗效有限,临床决策需权衡获益与毒性。
  • 需进一步研究NRG1重排肿瘤生物学以开发新治疗策略。

局限性

  • NRG1融合罕见,研究样本量有限(110例)。
  • 注册研究存在中心间检测方法和治疗异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although NRG1 fusions are oncogenic drivers across multiple tumor types including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 registry was thus established to characterize NRG1 fusion-positive lung cancers in the largest and most diverse series to date. METHODS: From June 2018 to February 2020, a consortium of 22 centers from nine countries in Europe, Asia, and the United States contributed data from patients with pathologically confirmed NRG1 fusion-positive lung cancers. Profiling included DNA-based and/or RNA-based next-generation sequencing and fluorescence in situ hybridization. Anonymized clinical, pathologic, molecular, and response (RECIST v1.1) data were centrally curated and analyzed. RESULTS: Although the typified never smoking (57%), mucinous adenocarcinoma (57%), and nonmetastatic (71%) phenotype predominated in 110 patients with NRG1 fusion-positive lung cancer, further diversity, including in smoking history (43%) and histology (43% nonmucinous and 6% nonadenocarcinoma), was elucidated. RNA-based testing identified most fusions (74%). Molecularly, six (of 18) novel 5' partners, 20 unique epidermal growth factor domain-inclusive chimeric events, and heterogeneous 5'/3' breakpoints were found. Platinum-doublet and taxane-based (post-platinum-doublet) chemotherapy achieved low objective response rates (ORRs 13% and 14%, respectively) and modest progression-free survival medians (PFS 5.8 and 4.0 months, respectively). Consistent with a low programmed death ligand-1 expressing (28%) and low tumor mutational burden (median: 0.9 mutations/megabase) immunophenotype, the activity of chemoimmunotherapy and single-agent immunotherapy was poor (ORR 0%/PFS 3.3 months and ORR 20%/PFS 3.6 months, respectively). Afatinib achieved an ORR of 25%, not contingent on fusion type, and a 2.8-month median PFS. CONCLUSION: NRG1 fusion-positive lung cancers were molecularly, pathologically, and clinically more heterogeneous than previously recognized. The activity of cytotoxic, immune, and targeted therapies was disappointing. Further research examining NRG1-rearranged tumor biology is needed to develop new therapeutic strategies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Drilon A, Duruisseaux M, Han JY, et al. Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. J Clin Oncol. 2021. PMID: 34077268. doi:10.1200/JCO.20.03307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。